During the past decade, Western Pennsylvania Cancer Institute conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 6 clinical trials were completed, i.e. on average, 120% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Western Pennsylvania Cancer Institute" #1 sponsor was "Celgene" with 6 trials, followed by "Pfizer" with 4 trials sponsored, "Celgene Corporation" with 3 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "Seagen Inc." with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Western Pennsylvania Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 3 trials as a collaborator, "AHN (Allegheny Health Network) Cancer Institute" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation" with 1 trials as a collaborator and "Jazz Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Western Pennsylvania Cancer Institute" are "Myelodysplastic Syndromes" (5 trials), "Brain and Central Nervous System Tumors" (2 trials), "Multiple Myeloma" (2 trials), "Acute Myeloid Leukemia" (1 trials) and "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome" (1 trials). Many other conditions were trialed in "Western Pennsylvania Cancer Institute" in a lesser frequency.

Most popular intervention types in "Western Pennsylvania Cancer Institute" are "Drug" (24 trials), "Biological" (3 trials), "Other" (3 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "CC-5013" (2 trials), "dasatinib" (2 trials), "leflunomide" (2 trials) and "lenalidomide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Western Pennsylvania Cancer Institute" are 27 trials for "All" genders.

Currently, there are NaN active trials in "Western Pennsylvania Cancer Institute". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Western Pennsylvania Cancer Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Western Pennsylvania Cancer Institute, 0 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".